Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2I19P)

• Drug Name: Barbituric acid derivative Drug Info
• Synonyms: Barbituric acid derivative; UNII-R1JI58032B; R1JI58032B; AC1MHEP3; DB01496; 2-thioxo-5-[[5-[2-(trifluoromethyl)phenyl]-2-furyl]methyl]hexahydropyrimidine-4,6-dione; 2-sulfanylidene-5-[[5-[2-(trifluoromethyl)phenyl]furan-2-yl]methyl]-1,3-diazinane-4,6-dione; 959343-20-5; 4,6(1H,5H)-Pyrimidinedione, dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3003157
  CAS Number: CAS 959343-20-5
  TTD Drug ID: DM2I19P

Molecule-Related Drug Atlas

Drug(s) Targeting GABA(A) receptor alpha-5 (GABRA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[2]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[3]
Basmisanil	DMQ8J0U	Alzheimer disease	8A20	Phase 2	[4]
RG-7816	DMD16JK	Autism spectrum disorder	6A02	Phase 1	[5]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[2]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[6]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[7]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[2]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[8]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[2]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ziprasidone	DMM58JY	Bipolar disorder	6A60	Approved	[9]
ALCURONIUM	DM2U4XQ	Anaesthesia	9A78.6	Approved	[10]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[11]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[12]
EVP-6124	DMLQO7F	Alzheimer disease	8A20	Phase 3	[13]
GTS-21	DMEN5KA	Parkinson disease	8A00.0	Phase 2	[14]
JNJ-39393406	DMUOEKM	Depression	6A70-6A7Z	Phase 2	[15]
ABT-126	DM2OS51	Alzheimer disease	8A20	Phase 2	[16]
TC-6987	DMNFP21	Asthma	CA23	Phase 2	[17]
AQW-051	DMD2RFO	Alzheimer disease	8A20	Phase 2	[18]

Drug(s) Targeting GABA(A) receptor alpha-2 (GABRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[19]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[3]
PF-4480682	DMWYJHC	Neuropathic pain	8E43.0	Discontinued in Phase 2	[20]
CGS-17867A	DMMZJY3	Alcohol dependence	6C40.2	Terminated	[21]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[19]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[6]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[7]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[19]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[8]
[3H]CGS8216	DMLP68J	Inflammation	1A00-CA43.1	Investigative	[19]

Drug(s) Targeting GABA(A) receptor alpha-1 (GABRA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[22]
Zolpidem	DMWOSKJ	Insomnia	7A00-7A0Z	Approved	[23]
Methoxyflurane	DML0RAE	Anaesthesia	9A78.6	Approved	[22]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[22]
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[24]
Clobazam - Lundbeck	DMW1OQ0	Anxiety disorder	6B00-6B0Z	Approved	[22]
Hexobarbital	DMQ314B	Anaesthesia	9A78.6	Approved	[22]
THIOCOLCHICOSIDE	DMEPWYA	Muscle spasm	MB47.3	Approved	[25]
Meprobamate	DMHM93Y	Anxiety		Approved	[22]
Zaleplon	DMGFWSM	Insomnia	7A00-7A0Z	Approved	[26]

Drug(s) Targeting GABA(A) receptor alpha-3 (GABRA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flumazenil	DMPCG2L	Benzodiazepine overdose	PC91	Approved	[27]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[3]
Adipiplon	DM821BS	Sleep-wake disorder	7A00-7B2Z	Phase 2	[28]
NS-2710	DMMUR6V	Anxiety disorder	6B00-6B0Z	Phase 2	[29]
AZD6280	DMFAZLU	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[30]
TBPS	DMFC3XP	Discovery agent	N.A.	Investigative	[27]
AMENTOFLAVONE	DMLRNV2	Discovery agent	N.A.	Investigative	[6]
Ro-15-3505	DM4NW3U	Discovery agent	N.A.	Investigative	[7]
isonipecotic acid	DMO1ZHE	Discovery agent	N.A.	Investigative	[27]
[3H]Ro154513	DMMBWKL	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-4 (CHRNA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trimethaphan	DMHF4IQ	Aneurysm	BD51.Z	Approved	[31]
Pentolinium	DM38VYQ	Hypotension	BA20-BA21	Approved	[32]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[33]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[34]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[35]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[33]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[36]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[37]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[37]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Inhibitor	[1]
GABA(A) receptor alpha-2 (GABRA2)	TTBMV1G	GBRA2_HUMAN	Inhibitor	[1]
GABA(A) receptor alpha-3 (GABRA3)	TT37EDJ	GBRA3_HUMAN	Inhibitor	[1]
GABA(A) receptor alpha-5 (GABRA5)	TTNZPQ1	GBRA5_HUMAN	Inhibitor	[1]
Neuronal acetylcholine receptor alpha-4 (CHRNA4)	TT4H1MQ	ACHA4_HUMAN	Antagonist	[1]
Neuronal acetylcholine receptor alpha-7 (CHRNA7)	TTLA931	ACHA7_HUMAN	Antagonist	[1]

References

• [1] Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408).
• [3] New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4.
• [7] The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8.
• [8] Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34.
• [9] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [10] Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
• [11] Clinical pipeline report, company report or official report of Roche (2009).
• [12] 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
• [13] Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
• [14] The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
• [15] Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
• [16] A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
• [17] ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [18] AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405).
• [20] WO patent application no. 2014,1515,17, Methods of improving microvascular integrity.
• [21] 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4.
• [22] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [23] Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
• [24] Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
• [25] 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
• [26] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406).
• [28] Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3.
• [29] GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202.
• [30] AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33.
• [31] Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
• [32] Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
• [33] Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
• [34] The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
• [35] (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.
• [36] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [37] Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
• [38] Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.